Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Easy BioXKRX:353810 -3.22%91 EBITDA Margin % is 13.10% as of Jun. 2026, which is 4% above its 10-year median of 12.65. GuruFocus rates XKRX:353810 with a GF Score™ of 91/100 and a GF Value™ of ₩7,883.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 943 Biotechnology companies, Easy Bio ranks better than 79.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Easy Bio's EBITDA for the
three
months ended in Jun. 2026 was ₩19,405 Mil. Easy Bio's Revenue for the
three
months ended in Jun. 2026 was ₩148,130 Mil. Therefore, Easy Bio's EBITDA margin for the quarter that ended in Jun. 2026 was 13.10%.
Easy Bio (XKRX:353810) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Easy Bio EBITDA Margin % Related Terms
Easy Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Easy Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:353810 vs VRTX, REGN, MRNA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Easy Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easy Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Easy Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Easy Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easy Bio (XKRX:353810) has a EBITDA Margin % of 13.10% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Easy Bio and its competitors. This is near median its historical median of 12.65. Over the past decade, Easy Bio's EBITDA Margin % has ranged from 11.16 to 17.81. According to the industry distribution chart, Easy Bio ranks #194 out of 943 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Easy Bio's EBITDA Margin % too high?
Easy Bio's current EBITDA Margin % of 13.10% is near median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 11.16 to a high of 17.81. Based on the distribution chart, Easy Bio ranks #194 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Easy Bio has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easy Bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Easy Bio ranks #194 out of 943 companies for EBITDA Margin %. This places Easy Bio in the top 21% of its industry — outperforming the majority of peers. Historically, Easy Bio's own EBITDA Margin % has ranged from 11.16 to 17.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Easy Bio and its competitors. Easy Bio's current EBITDA Margin % is 13.10%, which is near median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easy Bio stock overvalued right now?
Based on GuruFocus' analysis, Easy Bio (XKRX:353810) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩7,883.07, compared to a current price of ₩6,610.00 — trading 16.1% below its estimated fair value. The current EBITDA Margin % is 13.10%, which is near median its 10-year median of 12.65. Easy Bio's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Easy Bio (XKRX:353810), the current EBITDA Margin % is 13.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easy Bio (XKRX:353810) Overvalued in 2026?
Based on GuruFocus' analysis, Easy Bio stock appears to be undervalued.
The current stock price of ₩6,610.00 is trading 16.1% below its estimated GF Value™ of ₩7,883.07.
GuruFocus considers Easy Bio to be Modestly Undervalued.
Key valuation signals for XKRX:353810:
EBITDA Margin %: 13.10% (near median its 10-year median of 12.65)
GF Value™: ₩7,883.07 vs. price of ₩6,610.00 (16.1% below fair value)
No single metric tells the full story. See the XKRX:353810 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:353810 has been successfully added to your 
